Low-dose PLX5622 has been shown to prevent sepsis induced synaptic loss and cognitive impairment, underscoring the role of CSF1R signaling in inflammation related synaptic remodeling (Mein et al., 2023). The gene discussed is CSF1R; the disease is Cognitive impairment.